TRUMENBA targets a gene found in >99% of invasive MenB disease strains2
TRUMENBA works by targeting both subfamilies, A and B, of a lipoprotein—factor H binding protein (fHBP)—for which the gene is found in more than 99% of invasive MenB strains.2
The fHBP DiscoveryPfizer used a combined biochemical and immunological screening approach to identify surface-expressed proteins on MenB strains that were capable of producing antibodies that could kill diverse meningococcal strains. During this process, fHBP elicited robust bactericidal responses.1
Contact your Pfizer Sales Representative or call a Vaccine Specialist at
- Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2019.
- Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29-30):4739-4744.
- Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28(37):6086-6093.
- Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450.
Data on file. Pfizer Inc, New York, NY.
Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated January 21, 2020. Accessed July 6, 2020.
Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(2):1-9.
- Ewald AJ, McKeag DB. Meningitis in the athlete. Curr Sports Med Rep. 2008;7(1):22-27.